Browsed by
Month: March 2022

SYNAPS Dx Announces Investment by Semler Scientific

SYNAPS Dx Announces Investment by Semler Scientific

ROCKVILLE, Md.–(BUSINESS WIRE)–The announcement of a recent investment from Semler Scientific (SMLR) in SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease (AD), further positions DISCERN™ as a diagnostic for early AD. In its fourth quarter and year-to-date 2021 financial results, SMLR said, “SMLR previously announced its Fall 2020 investment in another private company, now known as SDx, whose product is a test for early AD, named DISCERN. SMLR believes its current products and services, and any future products or services that it may offer, positions it to provide valuable information to its customer base, which in turn permits them to better guide patient care.” ...  Read more